An interventional study of Rectal irrigation in Middle and Low Rectal Cancer and Rectal Cancer Surgery, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Rectal Neoplasms by Sun Yat-sen University — 19 open to participants now, 24 under way, 6 of them phase 3. Rectal Neoplasms · Sun Yat-sen University.
Among the 39 studies in Rectal Neoplasms by Sun Yat-sen University, this one has the largest planned enrollment of the 31 interventional ones that give a count, is one of 10 that started in 2025, is one of 8 with no phase, reaches primary completion later than 14 of the 23 other live ones, and was the 35th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →19 of the 39 studies in Rectal Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 17 · Phase 3 7
First in 2009; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,598 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 100 across the 31 interventional studies, 290 across the 8 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
1 of the studies in Rectal Neoplasms by Sun Yat-sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07651553Sun Yat-sen UniversityTransanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision | 2027-04-28 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Rectal Neoplasms by Sun Yat-sen University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summaries Trial Purpose The primary objective of this prospective, randomized, multicenter, open-label, parallel-controlled clinical trial is to evaluate whether intraoperative rectal irrigation during laparoscopic radical resection of low-to-mid rectal cancer reduces postoperative local recurrence rates compared to no irrigation. Secondary objectives include assessing overall survival, incidence of postoperative complications (e.g., anastomotic leakage, stenosis), and quality of life at 6 months (EORTC QLQ-C30 scale).
Participants Will:
This prospective, multicenter, randomized, open-label, parallel-controlled clinical trial aims to evaluate the efficacy of intraoperative rectal lavage in preventing local recurrence after laparoscopic radical resection for mid-to-low rectal cancer. Despite significant improvements in rectal cancer outcomes through standardized total mesorectal excision (TME) techniques and neoadjuvant therapy, local recurrence remains a serious clinical challenge with poor prognosis. Evidence suggests that exfoliated tumor cells within the bowel lumen may contribute to anastomotic seeding and subsequent local recurrence. Intraoperative manipulation of the tumor and use of circular staplers during anastomosis may further increase the risk of tumor cell dissemination. Rectal lavage represents a potential strategy to eliminate these free intraluminal malignant cells through mechanical flushing and/or cytotoxic effects of lavage solutions.
The study will enroll approximately 1,598 patients (accounting for a 10% dropout rate) across multiple centers in China. Participants must be 18-75 years of age with histologically confirmed adenocarcinoma of the rectum, where the tumor's distal margin is located within 10 cm of the anal verge. All patients must be scheduled to undergo laparoscopic radical resection with sphincter preservation. Key exclusion criteria include history of other malignancies, abdominoperineal resection (Miles procedure) or Hartmann's procedure, emergency surgery for bowel obstruction, severe organ dysfunction contraindicating surgery, pregnancy or lactation, and serious psychiatric disorders.
Eligible participants will be randomly assigned to either the experimental group (rectal lavage with normal saline/povidone-iodine solution) or the control group (no rectal lavage). Both groups will receive standardized laparoscopic TME procedures performed by experienced surgical teams, followed by identical Enhanced Recovery After Surgery (ERAS) protocols. The primary endpoint is the rate of local recurrence. Secondary endpoints include overall survival, incidence of postoperative complications (anastomotic leakage, pelvic infection, wound infection, intra-abdominal hemorrhage, urinary tract infection) graded according to the Clavien-Dindo classification system, and quality of life at 6 months postoperatively assessed using the EORTC QLQ-C30 questionnaire.
Participants will undergo scheduled follow-up assessments at 3, 6, 12, 24, 36, and 60 months after surgery, including clinical evaluations, imaging studies (CT/MRI), laboratory tests (CEA levels), and quality of life questionnaires. The study hypothesizes that the local recurrence rate will be 6% in the rectal lavage group compared to 10% in the control group. With a two-sided alpha of 0.05 and 80% statistical power, this sample size will provide adequate power to detect this clinically significant difference. This investigation will provide high-quality evidence regarding the role of intraoperative rectal lavage in preventing local recurrence after laparoscopic resection of mid-to-low rectal cancer, potentially establishing a simple yet effective intervention to improve oncological outcomes in this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Laparoscopic radical resection for rectal cancer followed by irrigation of the rectal cavity with normal saline / povidone-iodine
Procedure: Rectal irrigation
No irrigation of the rectal stump was performed after laparoscopic radical resection for rectal cancer.
Laparoscopic radical resection for rectal cancer followed by irrigation of the rectal cavity with normal saline / povidone-iodine
Postoperative local recurrence rate
The postoperative local recurrence rate following laparoscopic radical resection for mid-to-low rectal cancer is defined as the number of patients with recurrence divided by the total number of subjects.
Time frame: Within 3 years after radical resection of rectal cancer
Postoperative overall survival
Postoperative Overall Survival (OS) is defined as the length of time from the date of surgery to the date of death from any cause.
Time frame: Within 3 years after radical resection of rectal cancer
Postoperative complications
Postoperative complications-including anastomotic leakage, pelvic infection, surgical site infection, intra-abdominal hemorrhage, urinary tract infection, etc.-were graded according to the Clavien-Dindo classification system.
Time frame: Within 3 years after radical resection of rectal cancer
Health-related quality of life at 6 months
Health-related quality of life at 6 months postoperatively was assessed using the EORTC QLQ-C30 questionnaire.
Time frame: Within 3 years after radical resection of rectal cancer
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 35 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.